Evidence map›Paper›PMID 28318489›Full record

ArticleeLife2017

Deletion of the

Floris Foijer, Lee A Albacker, Bjorn Bakker, Diana C Spierings, Ying Yue, Stephanie Z Xie, Stephanie Davis, Annegret Lutum-Jehle, Darin Takemoto, Brian Hare and 5 more

Open access · goldAbstract read
In one paragraph

Article in eLife, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 65 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. MAD2L1 supports MYC-driven liver carcinogenesis in mice and predicts poor prognosis in human hepatocarcinoma.Toxicological sciences : an official journal of the Society of Toxicology · 2025
    Article
  5. The two sides of chromosomal instability: drivers and brakes in cancer.Signal transduction and targeted therapy · 2024
    Review
  6. Modeling specific aneuploidies: from karyotype manipulations to biological insights.Chromosome research : an international journal on the molecular, supramolecular and evolutionary aspects of chromosome biology · 2023
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 4 countries.

Floris FoijerEuropean Research Institute for the Biology of Ageing, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.ORCID 0000-0003-0989-3127
Lee A AlbackerDepartment of Systems Biology, Harvard Medical School, Boston, United States.
Bjorn BakkerEuropean Research Institute for the Biology of Ageing, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Diana C SpieringsEuropean Research Institute for the Biology of Ageing, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Ying YueDepartment of Systems Biology, Harvard Medical School, Boston, United States.
Stephanie Z XieDepartment of Systems Biology, Harvard Medical School, Boston, United States.
Stephanie DavisDepartment of Systems Biology, Harvard Medical School, Boston, United States.ORCID 0000-0002-0022-4210
Annegret Lutum-JehleDepartment of Systems Biology, Harvard Medical School, Boston, United States.
Darin TakemotoVertex Pharmaceuticals Incorporated, Cambridge, United States.
Brian HareVertex Pharmaceuticals Incorporated, Cambridge, United States.
Brinley FureyVertex Pharmaceuticals Incorporated, Cambridge, United States.
Roderick T BronsonRodent Histopathology Core, Dana-Farber/Harvard Cancer Center, Harvard Medical School, Boston, United States.
Peter M LansdorpTerry Fox Laboratory, BC Cancer Agency, Vancouver, Canada.
Allan BradleyWellcome Trust Sanger Institute, Hinxton, United Kingdom.
Peter K SorgerDepartment of Systems Biology, Harvard Medical School, Boston, United States.
Harvard University · USUniversity Medical Center Groningen · NLVertex Pharmaceuticals (United States) · USBC Cancer Agency · CAWellcome Sanger Institute · GB

Funding

Quantitative Analysis of Cell Death Pathways in CancerP01CA139980 · NCI · HARVARD MEDICAL SCHOOL · PI WEISSLEDER, MD, PHD, RALPH · 2010 to 2014
$9.0M
CELL AND TUMOR GENETICS OF MITOTIC ARREST CHECKPOINTSR01CA084179 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI SORGER, PETER KARL · 2000 to 2010
$3.5M
NCI NIH HHS P01 CA139980NCI NIH HHS R01 CA084179Wellcome Trust
6 · The paper itself

Abstract

Chromosome instability (CIN) is deleterious to normal cells because of the burden of aneuploidy. However, most human solid tumors have an abnormal karyotype implying that gain and loss of chromosomes by cancer cells confers a selective advantage. CIN can be induced in the mouse by inactivating the spindle assembly checkpoint. This is lethal in the germline but we show here that adult T cells and hepatocytes can survive conditional inactivation of the Mad2l1 SAC gene and resulting CIN. This causes rapid onset of acute lymphoblastic leukemia (T-ALL) and progressive development of hepatocellular carcinoma (HCC), both lethal diseases. The resulting DNA copy number variation and patterns of chromosome loss and gain are tumor-type specific, suggesting differential selective pressures on the two tumor cell types.

Indexed as

Chromosomal InstabilitySequence DeletionAnimalsCarcinoma, HepatocellularCell SurvivalDisease Models, AnimalHepatocytesLymphoma, T-CellMad2 ProteinsMiceM Phase Cell Cycle CheckpointsT-LymphocytesMad2l1 protein, mouseMad2 Proteinsaneuploidycancer biologychromosomal instabilitychromosomesgeneshumankaryotype heterogeneityMad2mousespindle checkpoint

Identifiers

PMID28318489
PMCPMC5400506
OpenAlexW2598957148

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.